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The GPCR CXCR4 is a chemokine receptor that by activation of its natural ligand 
SDF-1α is involved in the pathology of several diseases like cancer metastasis, 
leukemia cell progression and rheumatoid arthritis. The finding that CXCR4 plays a 
critical role for HIV-1 entry into T cells prompts additional motivation for the design of 
CXCR4 inhibitor. The establishment of the possible binding mode(s) for the 
cyclopentapeptide FC131 is decisive for the development of such inhibitor. Induced fit 
docking, which allowed flexibility for both the ligand and receptor structure, was used 
to generate ligand-receptor complexes. The resulting poses were compared based 
on their XP score and two ligand binding modes were suggested. In addition to this, 
mutational analysis on three CXCR4 residues which are believed to be important for 
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1.1 The CXCR4 receptor 
 
Chemokine receptors are integral membrane proteins which serve as specific binding 
sites for chemokines, which constitute a large family of chemotactic cytokines. The 
binding of chemokines to their specific chemokine receptors mediates diverse 
biological processes like angiogenesis, hematopoiesis, organogenesis and leukocyte 
trafficking under homeostatic and inflammatory conditions.1 
 
The chemokine receptor CXCR4 (receptor code 2.1:CHK:4:CXCR4)2 is an alpha-
helical 7 transmembrane (7TM) rhodopsin-like receptor which belongs to the large 
superfamily of receptor proteins called G protein-coupled receptors (GPCRs).  
 
The natural ligand for CXCR4 is stromal cell-derived factor (SDF-1α), also known as 
chemokine ligand 12 (CXCL12), is a small cytokine which belongs to the CXC 
chemokines.3 CXCL12 is a strong chemotactic for lymphocytes and also controls 
many other important biological processes like stem cell movement, development of 
neurons, angiogenesis and activation of leukocytes.4 
  
Beside the CD4 primary cellular receptor, CXCR4 was after a decade long search 
identified as the major coreceptor for human immunodeficiency virus type 1 (HIV-1) 
fusion and entry into T-cells.5 
 
Furthermore the CXCR4 receptor has been shown to be involved in many other 
diseases like cancer metastasis, leukemia cell progression and rheumatoid arthritis.6 
 
The involvement of CXCR4 in several different diseases has made it a potential 







1.2 CXCR4 antagonists from the literature 
Several types of CXCR4 antagonists have over the past decade been shown to 
exhibit potent and selective anti-HIV activity. The CXCR4 antagonists AMD3100, 
KRH-1636, T140 and FC131 are some of the agents in this class. The basic center in 
these molecules is one of the common features they have in common. 
The bicyclam AMD3100 is a symmetric compound consisting of two monocyclam 
rings connected by an aromatic 1,4-phenylenebis(methylene)-linker (Fig.1.1). 
AMD3100 demonstrates anti-HIV effect by inhibiting the CXCR4 co-receptor and 
blocking HIV-1 membrane fusion and entry to the host cell.7 
Mutational studies has revealed that Asp171, Asp262 and Glu288 are key interaction 
points for AMD31008. It suggested that Asp171 interacts with one of the bicyclam 
rings and the other ring is sandwiched between Asp262 and Glu288.9 
AMD070 is another small molecule which is believed to exhibit an anti-HIV activity 
through CXCR4 inhibition (Fig. 1.1). AMD070 is a derivate of AMD3100 and shows 
oral bioavailability.10 
 
Fig. 1.1: Structure of AMD3100 and AMD070. The basic center of the structures is marked 
with blue color. 
KRH-1636 (Kureha Chemical Industries) (Fig.1.2) is a relatively new low-molecular 
weight nonpeptide compound having a potent anti-HIV activity and reasonable 
bioavailability both in vivo and in vitro. KRH-1636 selectively hinders HIV-1 infection 



















Fig. 1.2: Structure of KRH-1636. Part of the structure which is colored with blue is the basic 
center of the molecule. 
 
The cyclopentapeptide (CPP) FC131 [c(Gly1-D-Tyr2-Arg3-Arg4-Nal5); Nal is 2-
naphthylalanine] (Fig.1.3), developed by molecular size reduction of another CXCR4 
antagonist, the 14-residue peptide T140 [Arg1-Arg2-Nal3-c(Cys4-Tyr5-Arg6-Lys7-D-
Lys8-Pro9- Tyr10-Arg11-Cit12-Cys13)-Arg14] (Fig.1.3) has also shown to be a potent 
CXCR4 antagonist. The size reduction (from T140 to FC131) was done based on the 
identification of the four bioactive amino acid residues Arg2, Nal3, Tyr5, and Arg14 of 




Fig. 1.3: Structures of T140 and the downsized peptide FC131 where Nal = L-3-(2 
naphthyl) alanine and Cit = L-citrulline. The basic center of the molecules is colored with blue. 
 
Side chain substitution at the different positions of FC131 resulted in analogs with 
varying affinity to the CXCR4 receptor. According to SAR studies, FC131 still remains 





1.3 Design of peptidomimetic CXCR4 antagonists 
 
Limited stability and oral bioavailability of peptides is a major drawback for the 
development into drugs.14 
 
The peptide mimetic design principles15,16,17 converts or modifies peptide antagonists 
into non-peptide or peptidomimetic compounds. A peptidomimetic molecule mimics 
the biological activity of the peptide, in addition to providing metabolic stability and 
oral bioavailability.18,19 
The small molecule CPP FC131, with a well defined 3D pharmacophore and 
established binding mode represents a good starting point for the development of 
peptidomimetic compounds.20-21 
1.4 Computer aided drug design 
 
The ideal situation for computer-aided drug design is that the detailed 3D molecular 
structure of the drug target and preferably also the 3D structure of the ligand-receptor 
complex is known. 
 
Though sequencing of the human genome has created the possibility of identifying 
many unknown proteins, the 3D structure of most membrane proteins, including 
CXCR4 is still unknown.22 
 
However, computer based homology modeling and docking programs have provided 
us the opportunity to predict the 3D structure of such proteins and also perform ligand 
docking, as described below. 
  
1.4.1 Homology modeling 
Homology modeling is a method of constructing and predicting an atomic resolution 
model of the target protein from its amino acid sequence based on an experimentally 




The method of homology modeling of membrane proteins is a relatively new and 
immature because of the few number of experimentally resolved membrane protein 
structures.23 
The four basic steps in homology modeling are: (1) identifying the template structure 
sequence, (2) aligning the query sequence with the template structure sequence, (3) 
building the model structure of the query based on the information from the template 
structure and (4) evaluating the predicted model.23 
Homology modeling is therefore a useful methodology in predicting undetermined 
protein structures like the CXCR4 receptor.24 
 
1.4.2 Docking Methods 
 
As the number of proteins with a known three-dimensional structure is increasing, the 
need for computational docking techniques, which involves the prediction of a 
ligand´s conformation and orientation in the target´s binding site, has grown rapidly 
particularly in the biotechnology and pharmaceutical industries.25,26 
 
Rigid receptor docking, which uses fixed receptor sites derived from high-resolution 
crystal structures, is one of the most widely used methods; however, this method 
often fails because many receptor-ligand interactions cause ligand-induced 
conformational changes. Rigid receptor docking is therefore not a suitable method 
where ligand-induced receptor/enzyme conformational change is relevant.27 
 
Because of the high demand of flexibility, most docking methods assume the protein 
to be rigid while many other docking programs consider the ligand to be flexible.28,24 
 
Induced fit docking (IFD) delivered by Schrodinger integrates two powerful programs 
called Prime (protein structure prediction) and Glide (rigid receptor docking), and is 
one of the most advanced docking programs which is especially useful when 
conformational change on both the receptor and ligand structure is induced during 





1.5 Objective of the thesis 
 
The main goal of this project is to identify a plausible binding mode for the 
cyclopentapeptide CXCR4 antagonist FC131. 
  
This will be done by induced fit docking of FC131 to a receptor model of CXCR4, 
which will be based on the newly published X-ray structure of the human β2-
adrenergic receptor.30 
 
Specifically, the focus will be on the three acidic residues (Asp171, Asp262 and 









































All calculations were done using commercially available software from Schrödinger31 
(2008 Suite) on a Dell Precision 390 N-Series workstation. Specifically, the following 
Schrödinger modules were used: MacroModel32 for ligand minimization, Prime33 for 
homology modelling, and the Induced Fit Docking protocol34 for ligand docking. 
 
2.2 Homology modeling of the CXCR4 Transmembrane helix (TMH) bundle 
 
The 3D structure model of the CXCR4 receptor was generated by using 
Schrödinger´s Prime module, which consists of the following 5 steps. 
 
2.2.1 Query (CXCR4) sequence 
 
The amino acid sequence of the human CXCR4 receptor (entry number P61073) was 
obtained from ExPASy (Expert Protein Analysis System) Proteomics Server35 and 
imported in FASTA format (a text based format where a single letter code is used to 
represent amino acid sequences). 
 
2.2.2 Template structure 
 
The high resolution crystal structure sequence of the human β2-adrenergic receptor 
(PDB-ID 2RH1_A), was selected as the template structure. 
 
2.2.3 Sequence alignment 
 
The “Align GPCR” option which is a specially designed program capable of aligning 
GPCRs by identifying transmembrane helixes and fingerprint (X.50)* matching was 
                                                           
* Ballesteros-Weinstein numbering is used throughout the text as superscripts to the protein 
numbering. Within each helix is a single, most conserved residue among the class A GPCRs. This 
residue is designated X.50, where X is the number of the transmembrane helix. All other residues on 




used to suggest the pair-wise alignment between the template and the query 
sequences. The suggested pair-wise alignment was manually edited in order to 
remove gaps in TMHs and achieve overlap between fingerprint residues of GPCRs.36 
 
2.2.4 Building the CXCR4 structure model 
 
The “Build structure” screen was used to predict the CXCR4 structure, omit structural 
discontinuities of more than 20 residues and optimize the side chains of the receptor 
model. 
 
2.2.5 Refining the modeled structure 
  
The termini and loops of the originally predicted receptor structure were removed in 
order to obtain only the 7 TMHs. 
  
The helical boundary (start-end) residues of the 7 TMHs of the predicted CXCR4 
receptor was defined based on the secondary structure assignment (SSA) of the 
template β2-adrenergic structure and were assigned as follows; [TMH1: Phe36-Tyr65 
(the first and last residues respectively); TMH2: Met72-Asn101; TMH3: Gly105-
Val139; TMH4: Leu150-Ile173; TMH5: Val197-Ser229; TMH6: Gln233-Phe264; and 
TMH7: His281-Leu301]. 
 
The remaining TMH bundle for CXCR4 was subjected, by using the protein 
preparation wizard, to addition of hydrogen atoms and capping of terminals. During 
cap termini, the program removes formal charges in the backbone structure by 
capping the N- and C-termini of the helixes with ACE (N-acetyl) and NMA (N-methyl 
amide) groups, respectively. 
 
The Ramachandran plot revealed that the dihedral angle, phi (ϕ), of the edited 7 TMH 
segment residues (Phe36, Met72, Gly105, Leu150, Val197, Gln233 and His281) was 
changed to 180o during capping. The angles were therefore adjusted to the value 






Table 2.1: The dihedral values after phi (φ) adjusted. 
Residue Phe36 Met72 Gly105 Leu150 Val197 Gln233 His281 
phi (ϕ) -61.1 -59.3 84.5 -58.8 -120 -41.6 -58.8 
 
The side chain conformations of the phi (φ) adjusted TMH bundle was finally 
optimized to its energetically most stable position resulting in the final TMH bundle of 
the CXCR4 receptor. 
 
2.2.6 The final receptor model 
 
The conformations of the two amino acid residues, Asp171 and Asp262, were 
changed based on visual inspection of the originally predicted receptor structure. 
Rotating Asp171 and Asp262 by a 180o from their original conformation was primarily 
meant to increase the exposure of these residues, and mainly of Asp171, to the 
binding pocket(s) of the receptor structure resulting in the hereafter called the 
wtCXCR4 receptor. 
 
2.3 Induced fit docking 
 
 
2.3.1 Preparing the ligand structure 
 
The starting conformation of the ligand molecule, FC131[c(Gly1-D-Tyr2-Arg3-Arg4-
Nal5], was generated from the proposed bioactive conformation of Ala3FC131 c(Gly1-
D-Tyr2-Ala3-Arg4-Nal5).20 
 
The residue Ala3 of Ala3FC131 was mutated to Arg3 resulting in the CPP FC131 
(Gly1-D-Tyr2-Arg3-Arg4-Nal5). The Macro Model program was used to minimize the 
energy of the ligand molecule. FC131 was built with positive charge on both 






2.3.2 Preparing the receptor model(s) 
 
The following two receptor categories were prepared and used in this project; (1) the 
originally predicted wild type (wtCXCR4) receptor, and (2) the mutant-receptor where 
the residues Asp262 and Glu288 of the wtCXCR4 receptor were mutated, one at a 
time, to Asn262 and Gln288, respectively to perform mutagenesis analysis. 
 
2.3.3 Induced Fit Docking protocol 
 
The default settings of Schrodinger´s IFD protocol were used in all the jobs except 
the values specified below. 
 
The receptor binding site represented by the energy grids of a cubic box, defined with 
46 Å and 14 Å for the outer and inner cubic boxes respectively, was used in all the 
jobs and was centered at residue number 116 (Tyr116), which represents the 
approximate center of the TMH bundle. 
 
In the docking jobs with constraints, the hydrogen bond acceptor atoms were 
selected from the workspace and applied in the respective jobs. 
 
Step 1.  Initial glide docking: 
During this stage, Glide generated 100 ligand-receptor complexes called poses. 
Step 2. Prime induced fit: 
The receptor side chains of every pose within 5 Å distance (default setting) of the 
ligand molecule were optimized. 
 
Step 3. Glide redocking: 
At this stage, each ligand structure within 30.0 Kcal/mol from the lowest energy pose 
and the top 20 resulting structure complexes from step 2 was redocked, using Glide 
XP, into their corresponding low energy receptor structures. 
 





FC131 docking to the wild type (wtCXCR4) receptor: 
1. IFD_FC131_wtCXCR4 
 





FC131 docking to the wtCXCR4 receptor with Asp262 and Glu288 mutated to 
Asn262 and Gln288 with constraint at the respective residues: 
5. IFD_FC131_ wtCXCR4_Asp-262-Asn_const262 






















































3 Results and discussion 
3.1 Homology model 
3.1.1 Choice of template 
 
Since sequence similarity usually implies significant structural resemblance, the 
sequence of a related homologous template protein can be used in the prediction of 
the structure of the query sequence.37 Selecting the right homolog template 
sequence is therefore a critical step toward the production of a good query structure. 
 
A chemokine receptor with highest possible resolution would have been an ideal 
template structure for CXCR4. However, this is not available, and instead we had to 
choose between the more distantly related GPCR receptors with known X-ray 
structure; these are Rhodopsin receptor (with resolution between 2.2-4.2 Å), β2-
Adrenergic receptor (resolution between  2.4-3.4 Å), β1-Adrenergic receptor (2.7 Å) 
and Adenosine A2A receptor (resolution of 2.6 Å)
38; where the structures are from 
Bovine/squid, Human, Turkey and Human respectively. 
 
The newly published 7 transmembrane crystal structure of human β2-adrenergic 
GPCR receptor, PDB code 2RH1_A and resolution of 2.4 Å was chosen based on its 
high resolution, the diffusible ligand (in contrast to Rhodopsin) and that the template 
is from the same species (human) as the query sequence. 
3.1.2 Alignment 
 
Literature data from GPCR family alignment shows that, the conserved fingerprint 
residues within the 7 transmembrane helices are: helix I [Gly (1.49) and Asn (1.50)], 
helix II [Leu (2.46) and Asp (2.50)], helix III [(Cys (3.25) and Asp (3.49), Arg (3.50), 
Tyr (3.51)], helix IV [Trp (4.50) and Pro (4.59)], helix V [Pro (5.50) and Tyr (5.58)], 
helix VI [Phe (6.44), Trp (6.48) and Pro (6.50)], and helix VII [Asn (7.49), Pro (7.50), 
and Tyr (7.53) of the NPXXY motif]36, where the most conserved residues in each 
transmembrane helixes of the rhodopsin-like GPCRs are known as the X.50 
residues. In the β2-adrenergic receptor, these are Asn51, Asp79, Arg131, Trp158, 




 The result of the pairwise alignment between the query and template sequences 
(Figure 3.1) showed that the conserved residues of the query and template sequence 
overlapped and were in good agreement with earlier sequence analysis of GPCRs36. 
 
 
Figure 3.1: Alignment of CXCR4 and the β2-adrenergic receptor sequences. The dashed line 
over the alignment sequences shows the helical regions of the CXCR4. The most conserved 
residues (X.50) are marked with a red colored rectangle over them. 
 
3.1.3 The final receptor model 
 
The Ramachandran plot (Figure 3.2) for the final receptor structure shows that the 
dihedral angles for most of the TMH residues of wtCXCR4 are in the typical region for 





Figure 3.2: Ramachandran plot for wtCXCR4, where the numbering represents residues (1) 
Gly105, (2) Val197, (3) Ser229, (4) Ala100 and (5) Asn101. 
 
Gly is less restricted because of its side chain (more flexible), and is fully allowed for 
Gly105 to be at the position shown; for the other residues, the deviation shown is 







         
Figure 3.3: 7 TMH bundle of wtCXCR4 receptor showing Asp171 (TMH4), Asp262 (TMH6) 
and Glu288 (TMH7). 
 
As shown in figure 3.3, the 7 TMHs of wtCXCR4 are organized in such a way that the 
residues Asp262, Glu288 are placed near to each other, whereas Asp171 is placed 
at a distance from these two residues. In addition to this, Asp171 is shielded from the 
core of the TMH bundle by transmembrane helix number 3. 
 
3.2 Docking results 
 
Favorable interactions were anticipated between the important pharmacophoric 
groups (Figure 3.3), D-Tyr2, Arg3, Arg4 and Nal5, of FC131 and the contact residues 








Figure 3.4: The structure of FC131. D-Tyr2, Arg3, Arg4 and Nal5 are the important 
pharmacophoric groups. The basic center of FC131 is marked with blue color.    
 
Since Arg3 and Arg4 of FC131 are positively charged, it is especially expected that 
these side chains of FC131 interact with the negatively charged residues (Asp171, 
Asp262 and Glu288) in the extracellular part of the CXCR4 TMH bundle; whereas the 
hydrophobic side chains D-Tyr2 and Nal5 make hydrogen/hydrophobic- and 
hydrophobic bonding, respectively. 
 
The extra precision (XP) scoring function in Glide is designed to identify ligand poses 
that would be expected to have unfavorable energies. Only active compounds will 
have available poses that avoid these penalties and also receive favorable scores for 
appropriate hydrophobic contacts between the receptor and the ligand, hydrogen-
bonding interactions, and so on. The main purpose of the XP method is to weed out 
false positives and to provide a better correlation between good poses and good 
scores. The XP score was therefore used rank the poses and the three pose from 
each job. The three poses with the best XP score measured in Kcal/mol are reported 













Table 3.1: FC131 docking to the wtCXCR4 receptor without constraint (job 1) 
Ligand 
side-chains 
Contact residues of the receptor structure 
Pose 1 Pose 2 Pose 3 
Arg4 Val99/His281 Ala98 Glu288 
Arg3 Asp262 Asp262 Ala98 
Tyr2             ∗∗ Gln200            ∗∗ 
Nal5 Phe292/Ala95/Phe49 Val99/Tyr45/Pro92 Ile48/Ala289/Val96 
XP score -13.82 -12.95 -11.95 
∗∗  The ligand side chain is not involved in interaction. 
 
From the result of job 1 (Table 3.1) and (Figure 3.5), we can clearly see that Asp262 
and Glu288 interacted with the ligand, whereas Asp171 was not involved in binding 
to FC131 for the top three poses. 
 
Figure 3.5: Figure showing the binding mode of the best scored pose form job 1. Arg3 and 
Arg4 are shown to involve in binding to the receptor. 
 
The purpose of job 2 (Table 3.2), with constraint on Asp171, was therefore to see if 
the ligand molecule is able to bind to this particular residue and also analyze the 





Table 3.2: FC131 docking to the wtCXCR4 receptor with constraint on Asp171 (job 2) 
Ligand 
side-chains 
Contact residues of the receptor structure 
Pose 1 Pose 2 Pose 3 
Arg4 Asp171/Tyr121 Asp171/Tyr121 Glu288 
Arg3 Asp171 Asp171 Asp171/Tyr121 
Tyr2          ∗∗ Asp262 Asp171 
Nal5 Tyr256/Tyr255/Leu120/Tyr116 Tyr256/Tyr255/Leu120/Tyr116 Val99/Val98 
XP score -10.90 -10.79 -8.63 
∗∗  The ligand side chain is not involved in interaction. 
 
 
Figure 3.6: Figure showing the binding mode of the best scored pose form job 2. Both Arg3 
and Arg4 are bounded to Asp171. 
 
As shown in table 3.2, interaction of Asp171 with the ligand molecule is possible; but 
the XP score has decreased by about 3 Kcal/mol, when compared with the XP score 





This decrease in the XP score corresponds to a 100-fold reduction in affinity, and 
indicates that, interaction of the ligand FC131 with Asp171 is unfavorable. This result 
is also in good agreement with what an earlier binding mode study of FC131 to the 
CXCR4 receptor has suggested.21 
Table 3.3: FC131 docking to the wtCXCR4 receptor with constraint on Asp262 (job 3) 
Ligand 
Side-chains 
Contact residues of the receptor structure 
Pose 1 Pose 2 Pose 3 
Arg4 His281/Val99            ∗∗ Ala98/Ser285 
Arg3 Asp262 Asp262/Thr287 Asp262 
Tyr2               ∗∗             ∗∗ Gln200 
Nal5 Phe292/Ala95/Phe49 Val99/Tyr45/Pro92 Ile48/Ala289/Val96 
XP score -13.89 -13.45 -12.96 
∗∗  The ligand side chain is not involved in interaction. 
 
The result from job 3 (Table 3.3) indicates the involvement of Asp262 in binding of 
Arg3, but the XP score from this job is very similar to the XP score from job 1 (Table 
3.1). 
 
Figure 3.7: Figure showing the binding mode of the best scored pose form job 3. Picture 




Table 3.4: FC131 docking to the wtCXCR4 receptor with constraint on Glu288 (job 4) 
Ligand 
side-chains 
Contact residues of the receptor structure 
Pose 1 Pose 2 Pose 3 
Arg4 Glu288/Ser285 Glu288/Ile285 Glu288/His281 
Arg3 Asp262 Asp262 Asp262 








XP score -13.02 -12.98 -12.92 
∗∗  The ligand side chain is not involved in interaction. 
 
Just like job 3 (Table 3.3), the result from job 4 (Table 3.4) does not show a 
significant change in the XP score when compared to job 1 (Table 3.1). The result 
from this job (Table 3.4) indicates the involvement of Glu288 in binding of Arg4. 
 
 
Figure 3.8: Figure showing the binding mode of the best scored pose form job 4. 





Since modeling (docking) is a theoretical approach which helps us predict the reality, 
the results from this work was taught to be supported by experimental data which 
could help us approve or disapprove the theoretical result. 
Site directed mutagenesis (SDM) is a technique which is widely used to perform such 
kinds of analysis. Mutation is created at a defined site in a molecule containing the 
desired change and the outcome of this mutation will be analyzed. 
The ligand molecule, FC131, was therefore sent to Copenhagen for SDM-studies, but 
the result which was expected to come at the beginning of this work, is still 
unfinished. The aim was to see if it was possible to correlate the experimental data 
with the docking data. 
Based on the following two mutational data, the effect of mutating Asp262Asn and 
Glu288Gln was examined in job 5 and job 6 respectively. 
(1) Mutational studies done by substituting Asp262 to Asn, has been shown to affect 
(decrease) HIV coreceptor activity39. It was also reported that mutation of Asp262 to 
Ala262 showed to reduce the anti-HIV activity of T140.40 
 
(2) Glu288Gln41 and Glu288Ala9 mutations has been shown to reduce signaling of 
SDf-1α significantly. 
 
Mutational data has confirmed the importance of Asp171 for binding of HIV gp12042, 
and binding mode analysis studies showed the involvement of Asp171 in binding with 
T14040 (which FC131 is derived from) and AMD3100.8 However, mutating Asp171 
was not necessary since binding of Asp171 to FC131 is shown to be unfavorable (job 
2 or Table 3.2). 
Table 3.5: FC131 docking to Asp262Asn mutated CXCR4 with constraint on Asn262 (job 5) 
Ligand 
side-chains 
Contact residues of the receptor structure 
Pose 1 Pose 2 Pose 3 
Arg4 Glu288/Tyr255 Glu288/His113 Glu288 
Arg3 Asn262/Gln200 Asn262 Asn262/Gln200 
Tyr2          ∗∗          ∗∗ Lys110 
XP score -9.55 -9.24 -9.21 




The result from job 5 (Table 3.5), with the best XP score of -9.55, shows a reduction 
in the XP score when compared to the result from job 1 (Table 3.1) and job 3 (Table 
3.3).  
 
Figure 3.9: Figure showing the binding mode of the best scored pose form job 5. As shown 
in the picture and also table 3.5, Arg3 binds to Asn262 and Arg4 to Glu288. 
 
A positive contribution of Asp262 to the ligand interaction was not suggested in a 
previous study.21 However, the decrease in the XP score when Asp262 is mutated to 
Asn262, shows that Asp262 contributes positively to the ligand-receptor interaction 
and seems important for the binding of the ligand molecule to the CXCR4 receptor. 
 
Table 3.6: FC131 docking to Glu288Gln mutated CXCR4 with constraint on Gln288 (job 6) 
Ligand 
side-chains 
Contact residues of the receptor structure 
Pose 1 Pose 2 Pose 3 
Arg4 Asp262 Asp262/Gln200 Asp262 
Arg3          ∗∗ Asp262 His113 
Tyr2 Ala98         ∗∗          ∗∗ 
XP score -14.09 -13.26 -13.04 




The result from job 6 (Table 3.6) shows a small increase in the XP score when 
compared to job 1 (Table 3.1). We saw from job 4 (Table 3.4) that Glu288 is involved 
in binding of FC131, and the affinity is therefore expected to decrease (by about 100-
1000 fold) when this residue is mutated to Gln288. 
 
The observed result from job 6 (Table 3.6), however, showed no/a small increase in 
affinity of the ligand when Glu288 is mutated to Gln. This is in contrast to what one 
would expect, and if this also was observed experimentally, it would be concluded 
that Glu288 is not involved in binding. This shows that the result from job 6 (Table 
3.6) is a false negative which leads to a wrong conclusion. 
  
 
Figure 3.10: Figure showing the binding mode of the best scored pose from job 6. The 
ligand is rotated by a 180o directing Arg3 to Glu288 and Arg4 to Asp262. 
 
Figure 3.10 shows that Gln288 binds to the backbone of FC131 and that the binding 
fashion of the ligand molecule is rotated by about 180o when we compare it with the 






3.3 Possible binding mode(s) of FC131 
 
Candidate binding mode for FC131, based on the four different docking jobs, (job 1, 
job 3 and job 4) plus one additional job (docking to wtCXCR4 with constraint on 
Asp262 and Glu288), which the result is not shown here, were used in analyzing the 
binding mode of FC131 to the CXCR4 receptor. 
The following two ligand binding modes (Table 3.7) were suggested by analyzing the 
contact residues of the three best poses from each job. 
Table 3.7 Contact residues of the representative binding modes. 
Pharmacophoric 
Groups 
Binding mode 1 Binding mode 2 
Arg4 Ala98,Val99,His281,Ser285 His281,Ile284,Ser285,Glu288 
Arg3 Asp262,Thr287 Asp262 






The positioning of the ligand molecule is almost “the same” in both of the suggested 
binding modes, i.e. the side chains of FC131 are directed to the same receptor 
residue (Tyr2 to Asp171, Arg3 to Asp262 and Arg4 to Glu288) in both cases. 
The main difference of these two binding modes is the placing of the backbone which 
is positioned near Glu288 in one case (binding mode 1) and near Asp262 (binding 





Figure 3.11: Binding mode 1 of FC131. The backbone is placed near Glu288. 
 
 







Based on induced fit docking of FC131 to a homology modeled 7TMH CXCR4 
receptor, the residues Asp262 and Glu288 seems to be involved in ligand binding by 
interacting with Arg3 and Arg4, respectively. Asp171, as shown from this present 
study, does not seem to be involved in binding to FC131.  
When docking to the Asp262Asn and Glu288Gln mutants, a reduction in affinity was 
observed for Asp262Asn, which would indicate that this residue is important for 
ligand-receptor interaction. For Glu288Gln, a small increase in affinity was observed, 
which would suggest that Glu288 is not involved in binding. However, since the 
involvement of Glu288 was already established, the docking result for Glu288Gln 
must be considered as a false negative. This indicates that the docking protocol used 
in the present study may not be suited for determining the effects of receptor 
mutations. 
Two possible binding modes of the ligand molecule are suggested. These two 
binding modes of the ligand molecule have similar binding fashion but the ligands are 
positioned in two different “binding pockets” of the receptor structure. 
The induced fit docking program used in this work allows flexibility of both the ligand 
and receptor structure which is important when ligand-induced conformational 
changes are relevant; this is one of the strongest side in the present study. 
The advantages of using the human β2-adrenergic receptor as template structure, 
when compared to templates that have been used in earlier studies (rhodopsin), is 
the diffusible ligand (in contrast to rhodopsin), the high crystal resolution and the 
origin (human). However, the template is not a chemokine receptor and this is one of 
the main drawbacks in this work. 
Another weakness in this study is the removal the extra- and intracellular loops; 
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